Jobs
-
DPI developer Chance Pharmaceuticals announced the completion of a financing round with participation from Heda Health Fund and Qihang Venture Capital, with proceeds intended to support Phase 3 trials of CXG87 inhaled dry powder budesonide… Read more . . .
-
Israeli biotech Polyrizon announced that it is beginning preclinical development of an intranasal naloxone formulation based on the company’s Trap and Target mucoadhesive technology. The company said that Fabio Sonvico of the University of Parma,… Read more . . .
-
Armata Pharmaceuticals announced details of an additional secured credit agreement with Innoviva Strategic Opportunities, the company’s largest shareholder. Armata said that it will pay interest at a 14% annual rate on the $10 million loan… Read more . . .
-
Emergent BioSolutions and Swiss biotech Rocketvax have announced that Emergent will make a strategic investment in Rocketvax parent company Swiss Rockets and will take over manufacturing and commercialization activities for 4 of Rocketvax’s intranasal vaccine candidates.… Read more . . .
-
According to Xlear, the US Department of Justice has asked a US District Court judge to dismiss a suit filed by the US Federal Trade Commission in 2021 accusing the company of violating the COVID-19… Read more . . .
-
McMaster University has announced the initiation of the AeroVax Phase 2 trial of its ChAd-triCoV/Mac inhaled vaccine against SARS-CoV-2. According to McMaster, the Canadian Institutes of Health Research has provided $8 million to support the… Read more . . .
-
Oragenics announced that it has submitted an Investigator’s Brochure application to Australian authorities seeking the go-ahead for a Phase 2 trial of ONP-002, a dry powder intranasal neurosteroid, for the treatment of mild traumatic brain… Read more . . .
-
Altamira Therapeutics said that it has received a notice of allowance from the US Patent and Trademark Office (USPTO) for a patent covering the formulation of Bentrio bentonite-based nasal spray. Bentrio received 510(k) clearance in… Read more . . .
-
Tiziana Life Sciences announced that it has submitted an IND to the FDA seeking approval for a Phase 2 trial of intranasal foralumab in patients with amyotrophic lateral sclerosis. In November 2024, the company announced… Read more . . .
-
According to DPI developer Iconovo, the company has received a grant worth SEK 670,000 from the EU’s Innowwide initiative, which encourages small and medium-sized EU companies to enter international markets. The grant will fund a market study… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden